Savings and coverage tools to help your patients start Tresiba® (insulin degludec)
Novo Nordisk has the best formulary coverage in the basal category
Tresiba® has ~87.5% national formulary coverage (commercial and Medicare Part D combined) and is covered nationwide on the majority of Medicare Part D plans.1,a-c Use the formulary tool to check coverage in your area.
Find out exactly which plans in your area include Tresiba®. Formulary status is believed to be accurate at the time of update but cannot be guaranteed.
aFormulary status subject to change. This information should not be used to make efficacy or safety comparisons between or among mentioned products.
bFormulary data are provided by Managed Markets Insight & Technology, LLC (MMIT) and are current as of February 2022.
cMedicare Part D data are on file with Novo Nordisk and are current as of February 2022.
What can patients expect to pay for Tresiba®?
Commercially insured patients
WITHOUT co-pay card
The vast majority of patients pay $35 or less per monthly co-pay2,d
WITH co-pay card
With the Tresiba® Savings Card, eligible patients pay as little as $25 or no more than $99 per prescription.e
Tresiba® is the less expensive option vs most other basal insulins for commercially insured patientsf
Medicare Part D patients
WITHOUT assistance
The majority of patients pay $50 or less per monthly co-pay2,d,g
WITH assistance
Low-Income Subsidy or Extra Help patients likely pay $9.85 per month or less3
- Nearly 50% of Part D Tresiba® patients receive Low-Income Subsidy or Extra Help benefits2
- Average Medicare co-pays for Tresiba® are comparable with other branded basal insulins2,f
dResults based on average monthly patient out-of-pocket cost for Tresiba® from IQVIA LAAD, January 2021-December 2021. Excludes cash-paying patients.
eEligibility and other restrictions apply.
fOther branded basal insulins include Basaglar®, Lantus®, Levemir®, Semglee®, and Toujeo®.
gExcludes Low-Income Subsidy or Extra Help Medicare patients.3
My$99Insulin
Eligible patients pay $99 for a monthly supply of any combination of Novo Nordisk insulin products (up to 3 vials or 2 packs of pens)h. Learn more at NovoCare.com.
See all the insulin affordability offerings at NovoCare.com, including the Novo Nordisk Patient Assistance Program (PAP), which offers Tresiba® at no cost to those who qualify for up to a yeari
iFull patient eligibility requirements can be found at NovoCare.com.
Request samplesj to start patients on Tresiba®
jYou must be a licensed practitioner who can legally prescribe medication in your state. (Request for product samples is limited to 1 request per health care professional.)
Indications and Usage for Tresiba® (insulin degludec) injection 100 U/mL, 200 U/mL
Tresiba® (insulin degludec) injection is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
Limitations of Use
Tresiba® is not recommended for treating diabetic ketoacidosis.
Important Safety Information
Contraindications
- Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients
Warnings and Precautions
- Never Share a Tresiba® FlexTouch® Pen, Needle, or Syringe Between Patients, even if the needle is changed. Patients using Tresiba® vials should never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens
- Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, or injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
- Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
- Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
- Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
- As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
- Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered
Adverse Reactions
- Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain
Drug Interactions
- There are certain drugs that may cause clinically significant drug interactions with Tresiba®.
- Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors
- Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones
- Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine
- Drugs that may blunt the signs and symptoms of hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine
Please click here for Tresiba® Prescribing Information.
References:
- Formulary data are provided by Managed Markets Insight & Technology, LLC (MMIT) and are current as of February 2022. Transaction and claims data are provided by Managed Markets Insight & Technology, LLC (MMIT) for the period February 2022. Medicare Part D cost shares are provided by Managed Markets Insight & Technology, LLC (MMIT), February 2022, and represent the initial coverage period.
- IQVIA LAAD, January 2021-December 2021
- Centers for Medicare & Medicaid Services. Advance Notice of Methodological Changes for Calendar Year (CY) 2022 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies – Part II. Accessed March 17, 2022. https://www.cms.gov/files/document/lis-memo.pdf. Published October 25, 2021.